From extending lifespan to bolstering the immune system, the drug’s effects are only just beginning to be understood.
Renowned cancer researcher Lewis Cantley is leaving Harvard to lead a new cancer center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.
September 14, 2012|
Cell biologist Lewis Cantley is making the move from Beantown to the Big Apple. The cancer researcher and National Academy of Sciences member is leaving his posts at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, Massachusetts, to head the newly established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital.
Cantley's discovery of phosphatidylinositol-3-kinase (PI-3-kinase) and illumination of its role in cancer and insulin signaling opened an entirely new perspective on the development of cancer and diabetes, forging a molecular link between metabolism and the diseases.
The new cancer center is set to open in 2014 and will house space for basic and clinical research, a tumor tissue bank, patient care, and other facilities. Cantley will be its director.
"We are on the brink of an evolution in cancer research and patient care that will dramatically change how our patients are diagnosed and how their diseases are managed," Cantley said in a statement. "I look forward to leading the new cancer center at Weill Cornell Medical College and NewYork-Presbyterian and the beginning of the next revolution in cancer care with unparalleled progress in discovery research, including the translation of our discoveries into novel, patient-centered approaches for cancer prevention, treatment, and cures."